Nucleolar stress: Friend or foe in cardiac function?

被引:2
|
作者
Yan, Daliang [1 ]
Hua, Lu [2 ]
机构
[1] Taizhou Peoples Hosp, Dept Cardiovasc Surg, Taizhou, Peoples R China
[2] Taizhou Peoples Hosp, Dept Oncol, Taizhou, Peoples R China
来源
基金
中国国家自然科学基金;
关键词
nucleolus; nucleolar stress; cardiac disease; nucleostemin; nucleophosmin; nucleolin; senescence; POLYMERASE-I TRANSCRIPTION; FACTOR TIF-IA; RIBOSOMAL-RNA SYNTHESIS; DNA-DAMAGE; PREMATURE SENESCENCE; HEART-FAILURE; NUCLEOSTEMIN; ACTIVATION; BIOGENESIS; PROTEIN;
D O I
10.3389/fcvm.2022.1045455
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Studies in the past decades have uncovered an emerging role of the nucleolus in stress response and human disease progression. The disruption of ribosome biogenesis in the nucleolus causes aberrant nucleolar architecture and function, termed nucleolar stress, to initiate stress-responsive pathways via nucleolar release sequestration of various proteins. While data obtained from both clinical and basic investigations have faithfully demonstrated an involvement of nucleolar stress in the pathogenesis of cardiomyopathy, much remains unclear regarding its precise role in the progression of cardiac diseases. On the one hand, the initiation of nucleolar stress following acute myocardial damage leads to the upregulation of various cardioprotective nucleolar proteins, including nucleostemin (NS), nucleophosmin (NPM) and nucleolin (NCL). As a result, nucleolar stress plays an important role in facilitating the survival and repair of cardiomyocytes. On the other hand, abnormalities in nucleolar architecture and function are correlated with the deterioration of cardiac diseases. Notably, the cardiomyocytes of advanced ischemic and dilated cardiomyopathy display impaired silver-stained nucleolar organiser regions (AgNORs) and enlarged nucleoli, resembling the characteristics of tissue aging. Collectively, nucleolar abnormalities are critically involved in the development of cardiac diseases.
引用
收藏
页数:9
相关论文
共 50 条
  • [21] Stress granules: friend or foe in neurodegenerative disorders?
    Xu, Shanshan
    Dantuma, Nico P.
    NEURAL REGENERATION RESEARCH, 2024, 19 (02) : 403 - 404
  • [22] Liver cirrhosis and thyroid function: Friend or foe?
    Vincken, Stefanie
    Reynaert, Hendrik
    Schiettecatte, Johan
    Kaufman, Leon
    Velkeniers, Brigitte
    ACTA CLINICA BELGICA, 2017, 72 (02) : 85 - 90
  • [23] Prokineticin Receptors in Cardiovascular Function: Foe or Friend?
    Nebigil, Canan G.
    TRENDS IN CARDIOVASCULAR MEDICINE, 2009, 19 (02) : 55 - 60
  • [24] Mitochondrial oxidative function in NAFLD: Friend or foe?
    Shum, Michael
    Ngo, Jennifer
    Shirihai, Orian S.
    Liesa, Marc
    MOLECULAR METABOLISM, 2020, 50
  • [25] Diastolic Tone-Friend and Foe of Cardiac Performance
    Meyer, Markus
    CIRCULATION-HEART FAILURE, 2023, 16 (12)
  • [26] Role of Autophagy in Proteostasis: Friend and Foe in Cardiac Diseases
    Li, Jin
    Zhang, Deli
    Wiersma, Marit
    Brundel, Bianca J. J. M.
    CELLS, 2018, 7 (12)
  • [27] Predictive scores, friend or foe for the cardiac arrest patient
    Nielsen, Niklas
    RESUSCITATION, 2012, 83 (06) : 669 - 670
  • [28] HIGH SENSITIVITY CARDIAC TROPONIN - A CARDIOLOGISTS FRIEND OR FOE?
    Schaefer, S.
    CARDIOLOGY, 2014, 128 : 136 - 136
  • [29] High-sensitive cardiac troponin: friend or foe?
    Twerenbold, Raphael
    Reichlina, Tobias
    Reiter, Miriam
    Mueller, Christian
    SWISS MEDICAL WEEKLY, 2011, 141
  • [30] Autoantibodies against cardiac troponin I: friend or foe?
    Jahns, Roland
    EUROPEAN JOURNAL OF HEART FAILURE, 2010, 12 (07) : 645 - 648